Odyssey Health Reports Q2 2025 Losses Amid Ongoing Financial Pressures and No Revenue Generation

Odyssey Health, Inc. (OTCBB: ODYY) released its quarterly report for the period ending January 31, 2025. The company continues to develop distinct medical technologies, including the CardioMap® heart monitoring device and the Save a Life choking rescue device, though none have received regulatory approval for commercial sale yet.

Key Financial Highlights:

• Loss from Operations: $156,593, down significantly from a loss of $1,157,430 in Q2 2024, reflecting an improvement of 86%.
• Total Revenue: No revenue recorded in both Q2 2025 and 2024.
• Net Income (Loss): $(220,126), contrasting with a net income of $13,277,566 from Q2 2024, highlighting a major decrease due to a lack of asset sale gains this period.
• Accumulated Deficit: $62,242,178 as of January 31, 2025, indicating continued financial struggles.
• Cash Position: Cash increased to $7,187 from $2,379, but overall assets decreased to $266,866 from $586,146 due to diminishing total asset value.
• General and Administrative Expenses: Reduced to $120,462 from $437,274, attributed to cost-cutting measures.
• Stock-Based Compensation: Dramatic reduction to $36,131 from $677,391, signaling decreased issuance and fewer unvested awards.

Positive Aspects:

• Substantial decrease in operating losses by 86%, showcasing efforts to reduce expenditures.
• Reduction in the stock-based compensation indicating tighter management of financial resources.
• Improved cash preservation efforts, despite the low cash level remaining a concern.

Negative Aspects:

• No revenue generation leading to reliance on equity and debt financing to sustain operations.
• Continued large accumulated deficit affecting financial stability and raising doubts about the company's ability to continue operations without major financing.
• Sizable interest expenses of $63,431, albeit reduced from prior periods, indicating ongoing financial obligations.
• Over 96 million shares outstanding, diluting equity for existing shareholders.

Conclusion: Despite its innovative approaches in developing medical technologies, Odyssey Health, Inc. is operating under considerable financial pressure with high expenditure levels and no current revenue. The company’s accumulated losses and lack of regulatory approval for its products raise significant concerns about its ongoing operations and ability to secure necessary capital.